Australia
Austria
Belgium
China
Czech Republic
Denmark
Estonia
Finland
France
Germany
Hungary
India
Ireland
Italy
Japan
Kazakhstan
Latvia
Lithuania
Malaysia
Netherlands
Norway
Poland
Singapore
Slovenia
Spain
Sweden
Thailand
UK
Ukraine
Investors
This section contains information about Orion as an investment.
Stock exchange releases
- 1/15/2025 Inside information: Orion upgrades full-year outlook for 2024 and provides preliminary information on financial performance for 2024
- 1/15/2025 Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2025 Annual General Meeting
- 1/13/2025 79,345 Orion Corporation A shares converted into B shares
- 12/19/2024 CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel
Press releases
- 1/7/2025 Orion’s collaboration partner Bayer submits application in China for third indication of darolutamide
- 12/30/2024 Orion and Marinus terminate agreement for ganaxolone in Europe
- 12/18/2024 Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics
- 11/22/2024 Orion Research Foundation grants EUR 1,109,000 for research in 2025
